Serum cytokeratin 19 fragment in advanced lung cancer: Could we eventually have a serum tumor marker?

ecancermedicalscience

Volumn 8, Issue 1, 2014, Pages

  Bastawisy, Ahmed El ^a   Azzouny, Mahmoud El ^b   Mohammed, Gamal ^b   Allah, Ahmad Awad ^b   Behiry, Eman ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b BENHA UNIVERSITY   (Egypt)

Author keywords

Cytokeratin 19 fragment; Lung cancer.

Indexed keywords

EID: 84894521461     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2014.394     Document Type: Article

References (17)

1. Jemal A et al (2011) Global cancer statistics CA Cancer J Clin 61 69-90. doi: 10.3322/caac.20107 pmid: 21296855
2. Mizuguchi S et al (2007) Cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer Ann Thorac Surg 83 (1) 216-21. doi: 10.1016/j.athoracsur.2006.08.042
3. A. Pastor et al (1997) Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis Eur Respir J 10 603-9. pmid: 9072992
4. Weiskopf B et al (1995) CYFRA21.1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role Chest 108 (1) 163-9. doi: 10.1378/chest.108.1.163
5. Ebert W, Muley T and Drings P (1996) Does the assessment of serum tumour markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res 16 (4B) 2161-8. pmid: 8694537
6. Paone G et al (1997) Validation of an algorithm to differentiate small cell lung cancer from non-small cell lung cancer patients by means of a tumour marker panel: analysis of the errors Br J Cancer 75 (3) 448-50. doi: 10.1038/bjc.1997.75 pmid: 9020496 pmcid: 2063371
7. Krismann M et al (1997) fur Pathologie, Berufsgenossenschaftliche Kliniken Bergmannsheil Bochum, Germany. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination Respir Med 91 (3) 135-42.
8. J. M. Bréchot et al (2002) Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients Service de Pneumologie, Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, France Available online 22 July 2002.
9. Zhao X and Wang M (2002) Clinical utility of serum tumour markers in lung cancer Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. m Lab Med 40 (3) 252-5.
10. Kasimir-Bauer S et al (2002) Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. University of Essen Medical School, Department of Internal Medicine (Cancer Research), West German Cancer Center, Essen, Germany. Sabine.kas.de Pol Merkur Lekarski. 13 (76) 294-7.
11. Chen TF et al (2004) CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor China. J UOEH 1 26 (4) 473-9.
12. Sugio K et al (2004) Tumour marker in primary lung cancer Arch Med Wewn 111 (6) 659-65.
13. Edelman MJ (2006) Novel cytotoxic agents for non-small cell lung cancer J Thorac Oncol 1 (7) 752-5. doi: 10.1097/01243894-200609000-00032
14. Uchikov A et al (2008) Diagnostic value of the serum tumour markers CEA and CYFRA 21-1 in patients with non-small cell lung cancer Lung Cancer 60 (3) 408-15.
15. Rosenblatt PY et al (2009) Lung cancer (NSCLC): CALGB 150304 Proc. 2009 ASCO Annual Meeting Session Type and Session Title: Poster Discussion Session, Tumour Biology and Human Genetics Abstract No:11020 J Clin Oncol 27 15s.
16. Qu YM et al (2010) Clinical significance of expressions of tumour markers in peripheral blood in non-small cell lung cancer China Biomarkers 15 (7) 594-601.
17. Wang J et al (2010) CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma Pathol Int 60 (2) 71-7.